Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:

• The H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 at 8:45 a.m. ET in New York, NY;
• The 3rd Annual Janney Healthcare Conference on September 10, 2019 at 9:05 a.m. ET in New York, NY; and
• The Cantor Global Healthcare Conference on October 3, 2019 at 5:20 p.m. ET in New York, NY.

Live webcasts of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the conference webcasts will be available on Concert’s website for two weeks following the presentations.

About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190829005072/en/

Justine Koenigsberg
(781) 674-5284
[email protected]

Source: Concert Pharmaceuticals, Inc.

You May Also Be Interested In

• Finance of America Earns 2026 Great Place To Work CertificationTM
• Arcadia Capital Advises InformedDNA on Divestiture of Genetic Testing Utilization Management Business Unit to Zyter
• BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing